RIST4721

DRUG5 trials

Sponsors

Aristea Therapeutics, Inc.

Conditions

Familial Mediterranean FeverHidradenitis SuppurativaInflammatory ResponsePalmoplantar Pustulosis

Phase 1

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

CompletedNCT04105959

Aristea Therapeutics, Inc.Inflammatory Response

Start: 2019-07-25End: 2019-12-09Updated: 2020-06-29

Phase 2

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

CompletedNCT03988335

Aristea Therapeutics, Inc.Palmoplantar Pustulosis

Start: 2019-02-13End: 2019-11-19Updated: 2022-04-05

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

TerminatedNCT05194839

Aristea Therapeutics, Inc.Palmoplantar Pustulosis

Start: 2022-01-05End: 2023-03-06Updated: 2023-06-29

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

TerminatedNCT05348681

Aristea Therapeutics, Inc.Hidradenitis Suppurativa

Start: 2022-07-18End: 2023-02-28Updated: 2023-06-13

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

WithdrawnNCT05448391

Aristea Therapeutics, Inc.Familial Mediterranean Fever

Start: 2022-09-13End: 2024-12-30Updated: 2023-02-13

Related Papers

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

Dermatology and Therapy2021-10-3012 citations